Active	Status	Sponsor type	Region	Phase	Filter
2 Active 14 Inactive 16 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Letybo (letibotulinumtoxinA-wlbg) / Hugel, Croma Pharma
2018-003983-30: Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESS III)	Not yet recruiting	3	353	Europe	BoNT/A-DP, Lyophilisate for solution for injection, Botulax	Croma-Pharma GmbH, CROMA-PHARMA GmbH	Moderate to severe glabellar lines, Moderate to severe glabellar lines, Body processes [G] - Biological Phenomena [G16]
2019-003481-41: Study to compare the efficacy, time to onset, and duration of effect of Botulinum Type A Toxins in the treatment of glabellar frown lines	Not yet recruiting	2	200	Europe	BoNT/A-DP, BOTOX Cosmetic, onabotulinumtoxinA, Lyophilisate for solution for injection, Botulax, BOTOX Cosmetic	Croma-Pharma GmbH, Croma-PHARMA GmbH	moderate to severe glabellar frown lines at maximum frown, Moderate to severe glabellar lines, Body processes [G] - Biological Phenomena [G16]